Rob Dillard

DocwireNews

The findings of an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with the targeted poly (ADP-ribose) polymerase inhibitor rucaparib, which recently became FDA approved. The study was published in the Journal of Clinical Oncology&reg;.In this phase II study (TRITON2), researchers assessed the safety and efficacy of rucaparib in treating men treat men with mCRPC who are predisposed to prostate cancer because of their genetic profile. Men whose cancer had progressed after completing hormone therapy and chemotherapy were eligible to participate. The University of Chicago Medicine Comprehensive Cancer Center was the second lead site internationally to enroll patients to this practice-changing study, which recruited 115 patients whose genetic screening revealed abnormalities in their BRCA genes. The patients were administered 600 mg of rucaparib twice a day. The results showed the objective response rate was 41%. Over half of the patients (53.9%) had improvements in their prostate-specific antigen (PSA) levels. Moreover, the researchers noted that in addition to demonstrating a significant anti-cancer response in mCRPC patients that had progressed on two prior lines of therapy, the rucaparib treatment had a manageable safety profile.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
PARP inhibitor becomes new treatment option for some men with advanced prostate cancer <a href="https://t.co/ij8Gg752OB">https://t.co/ij8Gg752OB</a>
&mdash; Cancer News Network (@cancer_network) <a href="https://twitter.com/cancer_network/status/1294377015085342721?ref_src=twsrc%5Etfw">August 14, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;There is a critical need for personalized medicines to effectively treat advanced prostate cancer,&rdquo; said&nbsp;Akash Patnaik, MD, PhD, national authority on prostate cancer research at the University of Chicago Medicine and one of the study authors, who presented the findings from this study at the Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology in San Francisco in February 2020 via a <a href="https://www.eurekalert.org/pub_releases/2020-08/uocm-pib081420.php">press release</a>. &ldquo;Approximately 12% of advanced prostate cancer patients have tumors that harbor a BRCA1 or BRCA2 alteration. We have arrived at an exciting inflection point in the field, as we now have the first FDA approved targeted therapy that can effectively treat a genetically defined subset of mCRPC patients, with poor prognosis and worse clinical outcomes on conventional treatments.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
PARP inhibitor becomes new treatment option for some men with advanced prostate cancer <a href="https://t.co/8hh2LhaFE2">https://t.co/8hh2LhaFE2</a>
&mdash; healthmedicinet (@healthmedicinet) <a href="https://twitter.com/healthmedicinet/status/1294588960770072576?ref_src=twsrc%5Etfw">August 15, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
PARP inhibitor becomes new treatment option for some men with advanced prostate cancer &ndash; Results from an international clinical trial found that men with advanced prostate cancer who have mutated &hellip; <a href="https://twitter.com/hashtag/NewsAndInformation?src=hash&amp;ref_src=twsrc%5Etfw">#NewsAndInformation</a> <a href="https://t.co/PseNPBW5nW">https://t.co/PseNPBW5nW</a> LIVING STRONG TELEVISION NETWORK
&mdash; LIVINGSTRONGTV.COM (@WhosoeverWill1) <a href="https://twitter.com/WhosoeverWill1/status/1294963857811574785?ref_src=twsrc%5Etfw">August 16, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;&nbsp;&nbsp;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

PARP Inhibitor Rucaparib Effectively Treats Men with Advanced Prostate Cancer

Oncology

The findings of an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with the targeted ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe